Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.
Type:
Application
Filed:
November 21, 2018
Publication date:
August 6, 2020
Applicants:
InflammaGen, LLC, The Regents of the University of California
Inventors:
Geert W. Schmid-Schonbein, Yung-Tsai (Andrew) Lee, Jeng Wei
Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.
Type:
Application
Filed:
November 21, 2018
Publication date:
June 13, 2019
Applicants:
InflammaGen, LLC, The Regents of the University of California
Inventors:
Geert W. Schmid-Schonbein, Yung-Tsai (Andrew) Lee, Jeng Wei
Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.
Type:
Grant
Filed:
October 26, 2016
Date of Patent:
November 27, 2018
Assignees:
The Regents of the University of California, Inflammagen, LLC
Inventors:
Geert W. Schmid-Schonbein, Yung-Tsai (Andrew) Lee, Jeng Wei
Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.
Type:
Application
Filed:
October 26, 2016
Publication date:
August 17, 2017
Applicants:
InflammaGen, LLC, The Regents of the University of California
Inventors:
Geert W. Schmid-Schonbein, Yung-Tsai (Andrew) Lee, Jeng Wei
Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.
Type:
Grant
Filed:
September 23, 2011
Date of Patent:
November 29, 2016
Assignees:
The Regents of the University of California, Inflammagen, LLC
Inventors:
Geert W. Schmid-Schonbein, Yung-Tsai (Andrew) Lee, Jeng Wei